| Literature DB >> 30962723 |
Ruifeng Zhang1, Xuhong Dang1, Zhongxin Zhang1, Yayi Yuan1, Yue Ren1, Zhikai Duan1, Yahui Zuo1.
Abstract
OBJECTIVE: Heavy ions have contributed to tumor site-specific radiotherapy and are a major health risk for astronauts. The purpose of this study was to investigate the changes in gene expression in peripheral lymphocytes of cancer patients and astronauts exposed to 12C ions, and identify suitable molecular biomarkers for health monitoring. We also aimed to observe the effects of treatment and the level of damage, by comparing the transcriptional profiles of human lymphocyte cell lines exposed to 12C ion beams at doses of 0-2.0 Gy.Entities:
Keywords: 12C ion beams; gene expression; human lymphocyte cell line; microarray assay
Year: 2019 PMID: 30962723 PMCID: PMC6434914 DOI: 10.2147/CMAR.S188959
Source DB: PubMed Journal: Cancer Manag Res ISSN: 1179-1322 Impact factor: 3.989
Primer sequences and amplification conditions for RT-PCR
| Gene | Gene-specific primer | Amplification conditions |
|---|---|---|
| F: 5′-ATCATTTGCACCATCCACCAG-3′ | 95°C for 30 seconds, | |
| F: 5′-GCAAGGACAGAGGTTCAGGAT-3′ | 95°C for 30 seconds, | |
| F: 5′-CCGAAGTAAGGAGCAGATGAGTG-3′ | 95°C for 30 seconds, | |
| β-actin | F: 5′-CCTCTCCCAAGTCCACACAG-3′ | 95°C for 30 seconds, |
Differentially expressed genes in human lymphocyte cell line irradiated by 12C ions
| Dose | Upregulated | Downregulated | Differentially expressed |
|---|---|---|---|
|
| |||
| 0.1 Gy | 1,113 | 853 | 1,966 |
| 0.5 Gy | 1,095 | 1,220 | 2,315 |
| 2.0 Gy | 1,055 | 1,356 | 2,411 |
| Common | 88 | 416 | 504 |
Downregulated genes with dose-dependent expression
| GenBank Accession | Gene name | Description | Fold change | ||
|---|---|---|---|---|---|
| 0.1 Gy | 0.5 Gy | 2.0 Gy | |||
| NM_025262 | −5.66 | −4.49 | −3.96 | ||
| NM_020354 | −5.47 | −3.54 | −3.37 | ||
| NM_175868 | −3.54 | −2.92 | −2.57 | ||
| XR_132464 | −3.22 | −2.97 | −2.75 | ||
| NM_006141 | −2.98 | −3.19 | −4.08 | ||
| NM_020219 | −2.86 | −2.72 | −2.34 | ||
| NM_001130518 | −2.71 | −3.16 | −4.00 | ||
| NM_130847 | −2.71 | −2.48 | −2.43 | ||
| BE795749 | UNKNOWN | −2.70 | −2.12 | −2.09 | |
| NM_001769 | −2.61 | −2.60 | −2.19 | ||
| NM_006979 | −2.43 | −2.91 | −2.97 | ||
| NM_001170406 | −2.18 | −2.26 | −3.00 | ||
| XR_108844 | Predicted: | −2.07 | −2.43 | −2.78 | |
| NM_001221 | −2.01 | −2.17 | −2.72 | ||
| NM_016603 | −2.01 | −2.26 | −2.69 | ||
| NM_175055 | −2.01 | −2.15 | −2.23 | ||
Upregulated genes with dose-dependent expression
| GenBank Accession | Gene name | Description | Fold change | ||
|---|---|---|---|---|---|
| 0.1 Gy | 0.5 Gy | 2.0 Gy | |||
| NM_002536 | 2.02 | 2.43 | 5.38 | ||
| NM_001294 | 2.02 | 2.09 | 3.55 | ||
| NM_021603 | 2.03 | 2.15 | 5.35 | ||
| NM_002999 | 2.04 | 2.17 | 5.93 | ||
| NM_001080494 | 2.09 | 2.37 | 5.38 | ||
| NM_001002880 | 2.13 | 2.15 | 2.73 | ||
| NM_015447 | 2.14 | 2.44 | 3.11 | ||
| NM_018416 | 2.24 | 2.43 | 3.05 | ||
| NM_002608 | 2.26 | 2.82 | 2.90 | ||
| NM_006103 | 2.45 | 2.89 | 3.15 | ||
| NM_207627 | 2.62 | 3.54 | 5.29 | ||
| NM_030641 | 4.23 | 3.37 | 2.68 | ||
Figure 1GO analysis of differentially expressed genes with dose-dependent relationships
Notes: (A) GO analysis of upregulated genes with dose-dependent relationships. (B) GO analysis of downregulated genes with dose-dependent relationships.
Abbreviations: GO, Gene Ontology.
Pathways of differentially expressed genes after irradiation by 12C ions
| Dose | Pathway | Gene number | |
|---|---|---|---|
| 0.1 Gy | Neuroactive ligand–receptor interaction | 20 | <0.001 |
| Cytokine–cytokine receptor interaction | 18 | <0.05 | |
| Glutamatergic synapse | 10 | <0.05 | |
| Cell adhesion molecules (CAMs) | 10 | <0.05 | |
| Taste transduction | 8 | <0.001 | |
| Vasopressin-regulated water reabsorption | 5 | <0.05 | |
| Maturity onset diabetes of the young | 5 | <0.001 | |
| Primary immunodeficiency | 4 | <0.05 | |
| Pantothenate and CoA biosynthesis | 3 | <0.05 | |
| 0.5 Gy | Systemic lupus erythematosus | 23 | <0.001 |
| Cytokine–cytokine receptor interaction | 23 | <0.05 | |
| Amoebiasis | 11 | <0.05 | |
| ECM–receptor interaction | 9 | <0.05 | |
| Complement and coagulation cascades | 9 | <0.05 | |
| Taste transduction | 9 | <0.001 | |
| Arachidonic acid metabolism | 7 | <0.05 | |
| Prion diseases | 5 | <0.05 | |
| 2.0 Gy | Systemic lupus erythematosus | 23 | <0.001 |
| MAPK signaling pathway | 21 | <0.05 | |
| Glutamatergic synapse | 13 | <0.05 | |
| Vascular smooth muscle contraction | 11 | <0.05 | |
| p53 signaling pathway | 10 | <0.001 | |
| Pancreatic secretion | 10 | <0.05 | |
| Apoptosis | 9 | <0.05 | |
| Complement and coagulation cascades | 8 | <0.05 | |
| Taste transduction | 8 | <0.05 | |
| Notch signaling pathway | 6 | <0.05 |
Pathways of genes with dose-dependent relationships
| Regulation | Pathway | Gene name | |
|---|---|---|---|
| Upregulated | Focal adhesion | 0.034 | |
| ECM–receptor interaction | 0.006 | ||
| Proximal tubule bicarbonate reclamation | 0.034 | ||
| Downregulated | Systemic lupus erythematosus | 0.021 | |
| Glycosaminoglycan biosynthesis – chondroitin sulfate | 0.036 |
Validation of microarray results for three randomly chosen genes by qRT-PCR
| Amplified gene | Irradiation group | Relative expression by PCR | Microarray fold change |
|---|---|---|---|
| 0.1 Gy | 1.35±0.01 | 2.62 | |
| 0.5 Gy | 1.58±0.03 | 3.54 | |
| 2.0 Gy | 3.45±0.06 | 5.29 | |
| 0.1 Gy | 3.36±0.44 | 4.23 | |
| 0.5 Gy | 3.00±0.25 | 3.37 | |
| 2.0 Gy | 1.79±0.11 | 2.68 | |
| 0.1 Gy | 0.45±0.02 | −5.66 | |
| 0.5 Gy | 0.56±0.01 | −4.49 | |
| 2.0 Gy | 0.59±0.07 | −3.96 |
Note:
P<0.05, statistically significant.